Company Profile
Viking Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Viking Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Viking Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Viking Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Viking Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
VKTX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Viking Therapeutics's catalysts are VK2735 injectable and oral obesity updates, with dose and tolerability data driving the next valuation move. The company still needs each readout to show that its GLP-1 / GIP story can stay competitive.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
Source: Viking Therapeutics
- 02
Viking Therapeutics to Participate at Upcoming Investor Conferences
Source: Viking Therapeutics
- 03
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Source: Viking Therapeutics
- 04
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Viking Therapeutics
- 05
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
Source: Viking Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.